The epithelial-mesenchymal transition and the estrogen-signaling in ovarian cancer

Current Drug Targets

Volumn 11, Issue 4, 2010, Pages 474-481

  Gallo, D ^a   Ferlini, C ^a   Scambia, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

E cadherin; EMT; Estrogens; Ovarian cancer; SLUG; SNAIL

Indexed keywords

ESTROGEN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN;

CANCER GROWTH; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; HUMAN; MESENCHYME CELL; OVARY CANCER; PHENOTYPE; PLASTICITY; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CADHERINS; CELL TRANSDIFFERENTIATION; DRUG DESIGN; EPITHELIAL CELLS; ESTROGENS; FEMALE; HUMANS; MESODERM; OVARIAN NEOPLASMS; PHENOTYPE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 77950814616     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790980385     Document Type: Review

References (62)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-592
3. Lukanova A, Kaaks R. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses. Cancer Epidemiol Biomarkers Prev 2005; 14: 98-107. Review. (Pubitemid 40165289)
4. Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol 2007; 14: 195-208.
5. O'Donnell AJ, Macleod KG, Burns DJ, Smyth JF, Langdon SP. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005; 12: 851-866
6. Armaiz-Pena GN, Mangala LS, Spannuth WA, et al. Estrous cycle modulates ovarian carcinoma growth. Clin Cancer Res 2009; 15: 2971-2978
7. Makar AP. Hormone therapy in epithelial ovarian cancer. Endocr Relat Cancer 2000; 7: 85-93. Review.
8. Colombo N, Van Gorp T, Parma G, et al. Ovarian cancer. Crit Rev Oncol Hematol 2006; 60: 159-179
9. Kiley J, Hammond C. Combined oral contraceptives: a comprehensive review. Clin Obstet Gynecol 2007; 50: 868-877 (Pubitemid 350059283)
10. Langdon SP, Hawkes MM, Lawrie SS, et al. Oestrogen receptor expression and the effects of oestrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer 1990; 62: 213-216 (Pubitemid 20242438)
11. Langdon SP, Crew AJ, Ritchie AA, et al. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur J Cancer 1994; 30A(5): 682-686
12. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002; 8: 2233-2239 (Pubitemid 34753595)
13. Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004; 66: 112-117
14. Hatch KD, Beecham JB, Blessing JA, Creasman WT. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991; 68: 269-271
15. Ahlgren JD, Ellison NM, Gottlieb RJ, et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol 1993; 11: 1957-1968
16. Gavert N, Ben-Ze'ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008; 14: 199-209.
17. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14: 818-829 Review. (Pubitemid 351757205)
18. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelial-mesenchymal transition: New insights in signaling, development, and disease. J Cell Biol 2006; 172: 973-981 Review.
19. Cardiff, R.D. Epithelial to mesenchymal transition tumors: fallacious or Snail's pace? Clin Cancer Res 2005; 11: 8534-8537
20. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res 2005; 65: 5996-6000. (Pubitemid 40994379)
21. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial- mesenchymal transitions. Nat Rev Mol Cell Biol 2006; 7: 131-142 Review.
22. Huber MA, Kraut N, Beug H. Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005; 17: 548-558 Review. (Pubitemid 41267170)
23. Moustakas A, Heldin CH. Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression. Cancer Sci 2007; 98: 1512-1520 (Pubitemid 47308444)
24. Zavadil J, Böttinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005; 24: 5764-5774
25. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev 2005; 26: 898-915. Review.
26. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009; 9: 265-273
27. Bailey JM, Singh PK, Hollingsworth MA. Cancer metastasis facilitated by developmental pathways: Sonic hedgehog, Notch, and bone morphogenic proteins. J Cell Biochem 2007; 102: 829-839 Review.
28. Wang Z, Li Y, Kong D, et al. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 2009; 69: 2400-2407
29. Horikawa T, Yang J, Kondo S, et al. Twist and epithelial-mesenchymal transition are induced by the EBV oncoprotein latent membrane protein 1 and are associated with metastatic nasopharyngeal carcinoma. Cancer Res 2007; 67: 1970-1978 (Pubitemid 46424213)
30. Julien S, Puig I, Caretti E, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 2007; 26: 7445-7456 (Pubitemid 350158710)
31. Wetmore C. Sonic hedgehog in normal and neoplastic proliferation: insight gained from human tumors and animal models. Curr Opin Genet Dev 2003; 13: 34-42. Review. (Pubitemid 36143925)
32. Cohen MM Jr. The hedgehog signaling network. Am J Med Genet A 2003; 123A: 5-28. Review.
33. Louro ID, Bailey EC, Li X, et al. Comparative gene expression profile analysis of GLI and c-MYC in an epithelial model of malignant transformation. Cancer Res 2002; 62: 5867-5873 (Pubitemid 35204747)
34. Li X, Deng W, Nail CD, et al. Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation Oncogene 2006; 25: 609-621
35. Li X, Deng W, Lobo-Ruppert SM, Ruppert JM. Gli1 acts through Snail and E-cadherin to promote nuclear signaling by beta-catenin. Oncogene 2007; 26: 4489-4498 (Pubitemid 47037042)
36. Van Aken E, De Wever O, Correia da Rocha AS, Mareel M. Defective E-cadherin/catenin complexes in human cancer. Virchows Arch 2001; 439: 725-751 Review. (Pubitemid 33141317)
37. Baum B, Settleman J, Quinlan MP. Transitions between epithelial and mesenchymal states in development and disease. Semin Cell Dev Biol 2008; 19: 294-308.
38. Peinado H, Portillo F, Cano A. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 2004; 48: 365-375 (Pubitemid 39360388)
39. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 2001; 22: 255-288 (Pubitemid 32458162)
40. Hudson LG, Zeineldin R, Stack MS. Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 2008; 25: 643-655 Review.
41. Ahmed N, Thompson EW, Quinn MA. Epithelial-mesenchymal interconversions in normal ovarian surface epithelium and ovarian carcinomas: an exception to the norm. J Cell Physiol 2007; 213: 581-588 Review. (Pubitemid 350058249)
42. Fujioka T, Takebayashi Y, Kihana T, et al. Expression of E-cadherin and beta-catenin in primary and peritoneal metastatic ovarian carcinoma. Oncol Rep 2001; 8: 249-255 (Pubitemid 33758073)
43. Voutilainen KA, Anttila MA, Sillanpää SM, et al. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 2006; 59: 460-467
44. Blechschmidt K, Sassen S, Schmalfeldt B, Schuster T, Höfler H, Becker KF. The E-cadherin repressor Snail is associated with lower overall survival of ovarian cancer patients. Br J Cancer 2008; 98: 489-495 (Pubitemid 351161237)
45. Imai T, Horiuchi A, Shiozawa T, et al. Elevated expression of E-cadherin and α -,β -, and γ-catenins in metastatic lesions compared with primary epithelial ovarian carcinomas. Hum Pathol 2004; 35: 1469-1476 (Pubitemid 40017986)
46. Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet 1994; 7: 98-102. (Pubitemid 24232388)
47. Rathi A, Virmani AK, Schorge JO, et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 2002; 8: 3324-3331 (Pubitemid 35340705)
48. Kurrey NK, Amit K, Bapat SA. Snail and Slug are major determinants of ovarian cancer invasiveness at the transcription level. Gynecol Oncol 2005; 97: 155-165 (Pubitemid 40403688)
49. Heldring N, Pike A, Andersson S, et al. Estrogen receptors: how do they signal and what are their targets. Physiol Rev 2007; 87: 905-931 Review. (Pubitemid 47084672)
50. Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997; 82: 4258-4265 (Pubitemid 27525550)
51. Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997; 138: 863-870 (Pubitemid 27089735)
52. Brandenberger AW, Tee MK, Jaffe RB. Estrogen receptor alpha (ER-alpha) and beta (ER-beta) mRNAs in normal ovary, ovarian serous cystadenocarcinoma and ovarian cancer cell lines: downregulation of ER-beta in neoplastic tissues. J Clin Endocrinol Metab 1998; 83: 1025-1028
53. Pujol P, Rey JM, Nirde P, et al. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58: 5367-5373 (Pubitemid 28551118)
54. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Muñoz A, Mor G. Absence of estrogen receptor-beta expression in metastatic ovarian cancer. Obstet Gynecol 2000; 96: 417-421
55. Lindgren PR, Cajander S, Bäckström T, Gustafsson JA, Mäkelä S, Olofsson JI. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 2004; 221: 97-104. (Pubitemid 38829727)
56. Ding JX, Feng YJ, Yao LQ, Yu M, Jin HY, Yin LH. The reinforcement of invasion in epithelial ovarian cancer cells by 17 beta-Estradiol is associated with up-regulation of Snail. Gynecol Oncol 2006; 103: 623-630 (Pubitemid 44602178)
57. Park SH, Cheung LW, Wong AS, Leung PC. Estrogen regulates Snail and Slug in the down-regulation of E-cadherin and induces metastatic potential of ovarian cancer cells through estrogen receptor alpha. Mol Endocrinol 2008; 22: 2085-2098
58. Hurt EM, Saykally JN, Anose BM, Kalli KR, Sanders MM. Expression of the ZEB1 (deltaEF1) transcription factor in human: additional insights. Mol Cell Biochem 2008; 318: 89-99.
59. Dannenmann C, Shabani N, Friese K, Jeschke U, Mylonas I, Brüning A. The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO. Cancer Biol Ther 2008; 7: 1460-1467
60. Toh Y, Nicolson GL. The role of the MTA family and their encoded proteins in human cancers: molecular functions and clinical implications. Clin Exp Metastasis 2009; 26: 215-227
61. Manavathi B, Singh K, Kumar R. MTA family of coregulators in nuclear receptor biology and pathology. Nucl Recept Signal 2007; 5: e010. Review.
62. Fujita N, Jaye DL, Kajita M, Geigerman C, Moreno CS, Wade PA. MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer. Cell 2003; 113: 207-219 (Pubitemid 36514972)